Searched for
FRENCH DRUG MAKER
Lupin completes acquisition of portfolio of brands from Anglo-French Drugs & Industries"India is critical in shaping Lupin's growth story going forward. This acquisition strengthens our position in the Indian market, where we ...- Japan drug showing 'favourable' results: ChinaChina's National Centre for Biotechnology development claimed that the drug Favipiravir, developed almost 25 years back, showed 'favourable...
- Sanofi bets on India with portfolio of drugs for diabetes, rare diseasesSanofi reported one of the sharpest falls in its global sales in the fourth quarter, owing to the decline in diabetes drug sales, a controv...
- Cipla’s inhalable insulin fails to get approval for trials on Indian patientsCipla had based its application to the panel on the bioequivalence studies with Exubra, an inhalation drug and device combination that was ...
- Sanofi bets on dengue vaccine, 5 other drugs to bolster India playFrench co plans to bring raft of innovative products, including preventive dengue vaccine; move may improve company’s prospects over its ri...
- Shantha Biotechnics CEO Harish Iyer moves to Bill and Melinda Gates Foundation as Senior AdvisorIyer was brought into Shantha in 2011 from Biocon at a time when the vaccine unit was facing action from WHO for its pentavalent vaccines.
- Lupin targets Rs 3,000 crore India sales by year-endSales in India currently generate about Rs 2,500 crore for the company, according to the All India Organisation of Chemists and Druggists A...
- Lupin, Unichem Laboratories among global companies fined by European CommissionAs per the European Commission Anti-trust ruling, Lupin has been fined 40 million euros, while Unichem Laboratories 13.96 million euros.
- Ten stocks in focus in Thursday morning tradeIndian markets are expected to trade higher. Here is a list of ten stocks which are likely to be in focus in trade today.
- Sanofi files cases against Glenmark on patent infringementSanofi had submitted its application to seek US Food and Drug Administration's (USFDA's) approval for its generic version of the drug on Ja...
- Coming soon: Novo Nordisk’s long-lasting insulin injectionNovo is betting big on Tresiba in the emerging markets after it failed to get an approval for the drug from the US Food and Drug Administra...
- Biocon Inks Pact with Mylan for generic insulinIn 2009, Mylan and Biocon had come together to develop five blockbuster biologic drugs in cancer and pain areas.
- French drug-maker Sanofi to buy animal health division of Dosch PharmaceuticalsFrench drug-maker Sanofi has entered into an agreement to acquire the animal health division of Indian firm Dosch Pharmaceuticals for an un...
- Dr Reddy's launches Fexofenadine HCl in USDr Reddy's Laboratories today announced the launch of generic version of Allegra -- Fexofenadine HCl -- tablets in the US market.
- Sanofi extends $18.5 bn bid for Genzyme againIn a statement Sanofi-aventis said its offer of $69 per Genzyme share was extended till February 15 midnight.
- Sun Pharma suffers second setback in US patent rowSun Pharmaceutical Industries suffered its second setback in the US litigation within four days after a New Jersey district court decided t...
- US court bans Sun from selling Eloxatin: Sanofi AventisFrench drug maker Sanofi Aventis SA on Friday said a New Jersey US district court ordered Sun Pharma to stop selling its generic version of...
- Sanofi-Aventis to buy Chattem for $1.9 bnFrench drug maker Sanofi-Aventis SA to buy US health care company Chattem Inc for about $1.9 billion in cash.
- Sanofi-Aventis scans India for acquisitionsSanofi-Aventis which bought companies in Brazil, Mexico, and the home-grown Shanta Biotech this year, has sent a delegation to India to fin...
- Zentiva recommends shareholders reject Sanofi Aventis' bidThe board of Czech generic drugs maker Zentiva N.V. said it has recommended that its shareholders reject a takeover offer from French pharm...
Load More
